An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses.
These are the first data to highlight the prognostic value of MGMT methylation beyond the IDH1/2 mutation status test currently used to help predict glioma patient survival outcomes.
An Australian team is studying a DNA-based vaccine that the lead investigator feels could be “transformative” in the care of advanced colorectal cancer.
This study is the first to show significantly improved OS from single-agent treatment in this particularly difficult to treat population.
Preoperative pain, prothrombin time activity (PTA), albumin, urine protein, and postoperative chemotherapy appeared to be associated with prognosis.
Many MM patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed, and several factors may account for this.
De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.
In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology.
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile.
In RCC patients on anti–PD-1 therapy, besides the indel count link to better OS, baseline tumor infiltration with M2 macrophages predicted improved PFS.